Book contents
- Stories of Stroke
- Stories of Stroke
- Copyright page
- Contents
- Contributors
- Why This Book Needed to Be Written
- Preface
- Part I Early Recognition
- Part II Basic Knowledge, Sixteenth to Early Twentieth Centuries
- Part III Modern Era, Mid-Twentieth Century to the Present
- Types of Stroke
- Some Key Physicians
- Imaging
- Care
- Treatment
- Chapter Forty Three Clinical Stroke Trials
- Chapter Forty Four Heparin
- Chapter Forty Five Warfarin
- Chapter Forty Six Direct Oral Anticoagulants
- Chapter Forty Seven Aspirin
- Chapter Forty Eight Other Antiplatelets
- Chapter Forty Nine Other Medical Treatments
- Chapter Fifty Neuroprotection
- Chapter Fifty One Thrombolysis
- Chapter Fifty Two Treatment of Cerebral Venous Thrombosis
- Chapter Fifty three Recovery and Rehabilitation
- Chapter Fifty Four Carotid Artery Surgery
- Chapter Fifty Five Angioplasty and Stenting
- Chapter Fifty Six Endovascular Treatment of Acute Ischemic Stroke
- Chapter Fifty Seven Brain Aneurysm Treatment
- Chapter Fifty Eight Medical and Surgical Treatments of Intracerebral Hemorrhage
- Chapter Fifty Nine Treatment of Vascular Malformations
- Part IV Stroke Literature, Organizations, and Patients
- Index
- References
Chapter Forty Eight - Other Antiplatelets
from Treatment
Published online by Cambridge University Press: 13 December 2022
Book contents
- Stories of Stroke
- Stories of Stroke
- Copyright page
- Contents
- Contributors
- Why This Book Needed to Be Written
- Preface
- Part I Early Recognition
- Part II Basic Knowledge, Sixteenth to Early Twentieth Centuries
- Part III Modern Era, Mid-Twentieth Century to the Present
- Types of Stroke
- Some Key Physicians
- Imaging
- Care
- Treatment
- Chapter Forty Three Clinical Stroke Trials
- Chapter Forty Four Heparin
- Chapter Forty Five Warfarin
- Chapter Forty Six Direct Oral Anticoagulants
- Chapter Forty Seven Aspirin
- Chapter Forty Eight Other Antiplatelets
- Chapter Forty Nine Other Medical Treatments
- Chapter Fifty Neuroprotection
- Chapter Fifty One Thrombolysis
- Chapter Fifty Two Treatment of Cerebral Venous Thrombosis
- Chapter Fifty three Recovery and Rehabilitation
- Chapter Fifty Four Carotid Artery Surgery
- Chapter Fifty Five Angioplasty and Stenting
- Chapter Fifty Six Endovascular Treatment of Acute Ischemic Stroke
- Chapter Fifty Seven Brain Aneurysm Treatment
- Chapter Fifty Eight Medical and Surgical Treatments of Intracerebral Hemorrhage
- Chapter Fifty Nine Treatment of Vascular Malformations
- Part IV Stroke Literature, Organizations, and Patients
- Index
- References
Summary
During the final years of the nineteenth century, clinicians and researchers became aware of the role that platelets played in blood clotting and bleeding. During the early 1880s in Turin, Italian physician, histologist, and researcher Giulio Bizzozero used comprehensive intravascular microscopy and in vitro flow chamber studies to identify the role of platelets in both hemostasis and thrombosis [1,2]. Sir William Osler in 1886 established that platelets contributed to human thrombotic disorders, discovering them in white thrombi in atheromatous aortic lesions and on diseased heart valves [1,3].
- Type
- Chapter
- Information
- Stories of StrokeKey Individuals and the Evolution of Ideas, pp. 455 - 464Publisher: Cambridge University PressPrint publication year: 2022
References
Notes and References
Coller, BS. Historical perspective and future directions in platelet research. J. Thromb. Haemost. 2011;9(suppl 1):374–395.CrossRefGoogle ScholarPubMed
Bizzozero, G. Su di un nuovo elemento morfologico del sangue dei mammiferi e della sua importanza nella trombosi e nella coagulazione. L’Osservatore 1881;17:785–787.Google ScholarGoogle Scholar
Osler, W. On certain problems in the physiology of the blood corpuscles. Med. News 1886;48:421–425. The stroke contributions of Sir William Osler and his medical textbooks are discussed further in Chapter 14.Google Scholar
Gustav Victor Rudolf Born. Wikipedia. Available at https://en.wikipedia.org/wiki/Gustav_Victor_Rudolf_Born.Google Scholar
Born, GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–929.Google ScholarGoogle Scholar
Brownlee, C. Biography of Barry S. Coller. Proc. Natl. Acad. Sci. U.S.A 2004 Sep 7;101(36):13111–13113.Google Scholar
The history and evolution of the antiplatelet introduction of aspirin by Bayer is discussed in detail in Chapter 46.Google Scholar
Personal communication from Wolfgang Eisert, who directed dipyridamole research at Boehringer-Ingelheim.Google Scholar
Eisert, W, Gruber, P. Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation. US Patent 6015577A. https://patents.google.com/patent/US6015577A/en.Google Scholar
Sullivan, J, Harken, D, Gorlin, R. Pharmacologic control of thromboembolic complications of aortic valve replacement. N. Engl. J. Med. 1971;284:1391–1394.CrossRefGoogle Scholar
Fields, WS, Yatsu, F, Conomy, J, et al. Persantine-aspirin trial in cerebral ischemia: The American-Canadian Cooperative Study group. Stroke 1983;14:97–103.Google ScholarGoogle Scholar
ESPS Group. European Stroke Prevention Study (ESPS): Principal endpoints. Lancet 1987; 2:1351–1354.Google ScholarGoogle Scholar
The ESPRIT Study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial. Lancet 2006;367:1665–1673.CrossRefGoogle Scholar
Verro, P, Gorelick, PB, Nguyen, D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: A meta-analysis. Stroke 2008;39(4):1358–1363.Google Scholar
Ikeda, Y, Kikuchi, M, Murakami, H. Comparison of the inhibitory effects of cilostazole, acetylsalicylic acid, and ticlopidine on platelet function ex vivo: Randomized, double-blind cross-over study. Drug Res. 1987;37:563–566.Google ScholarGoogle Scholar
Gotoh, F, Tohgi, H, Hirai, S, et al. Cilostazole stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J. Stroke Cerebrovasc. Dis. 2000;9:147–157.Google Scholar
Kwon, SU, Cho, Y-J, Koo, J-S, et al. Cilostazole prevents the progression of the symptomatic intracranial stenosis: The multicenter double-blind placebo-controlled trial of cilostazole in symptomatic intracranial arterial stenosis. Stroke 2005;36:782–786.CrossRefGoogle ScholarPubMed
Quinn, MJ, Fitzgerald, DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667–1672.Google ScholarGoogle Scholar
Hass, WK, Easton, JD, Adams, HP Jr, Pryse-Phillips, W, Molony, BA, Anderson, S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke study group. N. Engl. J. Med. 1989;321:501–507.Google ScholarGoogle Scholar
Maffrand, JP. The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today? C. R. Chim. 2012;15(8):737–743.CrossRefGoogle Scholar
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet 1996;348:1329–1339.Google Scholar
Diener, HC, Bogousslavsky, J, Brass, LM, Cimminiello, C, Csiba, L, Kaste, M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–337.Google ScholarGoogle Scholar
Bhatt, DL, Fox, KA, Hacke, W, Berger, PB, Black, HR, Boden, WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 2006;354:1706–1717.Google Scholar
Wang, Y, Wang, Y, Zhao, X, et al. and Johnston SC for the CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N. Engl. J. Med. 2013;369:1–13.Google Scholar
Johnston, SC, Easton, JD, Farrant, M, et al. for the Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N. Engl. J. Med. 2018;379:215–225.CrossRefGoogle ScholarPubMed
Johnston, SC, Amarenco, P, Albers, GW, et al. for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N. Engl. J. Med. 2016;375:35–43.Google Scholar
Johnston, SC, Amarenco, P, Denison, H, et al. for the THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N. Engl. J. Med. 2020;383:207–217.Google Scholar
Coller, BS. Anti-GPIIb/IIIa drugs: Current strategies and future directions. Thromb. Haemost. 2001;86(1):427–443.Google Scholar
Lefkovits, J, Plow, EF, Topol, EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 1995;332:1553–1559.CrossRefGoogle ScholarPubMed
Adams, HP Jr, Effron, MB, Torner, J, Davalos, A, Frayne, J, Teal, P, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke 2008;39:87–99.Google Scholar
Topol, EJ, Easton, D, Harrington, RA, Amarenco, P, Califf, RM, Graffagnino, C, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399–406.Google Scholar